Investors in Theravance Biopharma, Inc. (TBPH) need to pay close attention to the stock based on moves in the options market lately. That is because the March 20, 2026 $10 Put had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It co ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Sc ...

Several biotech and healthcare stocks posted notable gains in after-hours trading on Friday, driven by regulatory developments, financing updates, and investor sentiment.Atossa Therapeutics, Inc. (ATOS) rose 12.98% to $0.69, up $0.080 after announcing that the U.S. Food and Drug Administration's Office of Orphan Products Development granted Orphan Drug Designation to (Z)-endoxifen for the treatment of Duchenne muscular dystrophy. The designation marks a significant milestone for the company's pipeline.Immu ...

Market Overview - U.S. stock futures showed mixed results, with Dow futures declining by 0.2% [1] Company-Specific Movements - Jefferson Capital Inc (NASDAQ:JCAP) experienced a significant drop of 4.4%, trading at $22.00, following the announcement of a secondary offering of 10 million shares [1] - MOBIX LABS, INC. (NASDAQ:MOBX) fell sharply by 25.4% to $0.24 due to plans for a common stock offering [2] - Datavault AI Inc (NASDAQ:DVLT) shares decreased by 12.4% to $1.26 after a previous surge of 43% on Monday, linked to a nationwide deployment announcement [2] - BitVentures Ltd – ADR (NASDAQ:BVC) saw a decline of 9.7% to $13.33 after a 5% gain on Monday [2] - Zenas Biopharma Inc (NASDAQ:ZBIO) tumbled by 6.6% to $15.50 following a 52% drop on Monday due to Phase 3 trial results [2] - Theravance Biopharma Inc (NASDAQ:TBPH) dipped 6% to $17.07 after a 3% decline on Friday [2] - Graphic Packaging Holding Co (NYSE:GPK) fell 4.9% to $14.70 ahead of its fourth quarter financial results announcement [2] - ATRenew Inc (NYSE:RERE) declined by 4.1% to $5.65 after a 9% gain on Monday [2] - Rezolve AI PLC (NASDAQ:RZLV) fell 3.7% to $3.07 in pre-market trading [2] - NovaBay Pharmaceuticals Inc (NYSE:NBY) slipped 3.4% to $6.52 after a 15% jump on Monday [2] - Starfighters Space Inc (NYSE:FJET) decreased by 3.3% to $9.08 after a 10% dip on Monday [2]

Market Overview - U.S. stock futures showed positive movement, with Nasdaq 100 futures increasing by over 150 points on Monday [1] Company-Specific Movements - mF International Limited (NASDAQ:MFI) experienced a significant decline, falling 4.6% to $17.61 in pre-market trading after filing for a mixed shelf [1] - SBC Medical Group Holdings Inc (NASDAQ:SBC) dropped 18.9% to $3.51 in pre-market trading [2] - Aimei Health Technology Co Ltd (NASDAQ:AFJK) decreased by 7.7% to $70.00 in pre-market trading [2] - Theravance Biopharma Inc (NASDAQ:TBPH) fell 6% to $17.07 in pre-market trading, following a 3% decline on Friday [2] - Comcast Corp (NASDAQ:CMCSA) tumbled 4.6% to $28.18 in pre-market trading [2] - Equinor ASA (NYSE:EQNR) decreased by 3.6% to $23.66 in pre-market trading after a 4% gain on Friday [2] - Canadian Natural Resources Ltd (NYSE:CNQ) fell 3.4% to $33.15 in pre-market trading [2] - Xpeng Inc – ADR (NYSE:XPEV) slipped 3.3% to $19.75 in pre-market trading [2] - Two Harbors Investment Corp (NYSE:TWO) declined 3.2% to $10.24 in pre-market trading [2] - NetEase Inc (NASDAQ:NTES) fell 2.9% to $143.29 in pre-market trading, following the announcement of Yingfeng Ding's retirement from his position as executive vice president and head of the Interactive Entertainment Group [2]

Core Insights - Zacks Premium offers various tools to enhance stock market investment confidence and knowledge [1][2] Zacks Style Scores - Zacks Style Scores are indicators that rate stocks based on value, growth, and momentum methodologies, helping investors identify stocks likely to outperform the market in the next 30 days [3][4] - Each stock is rated from A to F, with A indicating the highest potential for outperformance [4] Value Score - The Value Style Score focuses on identifying undervalued stocks using financial ratios like P/E, PEG, and Price/Sales [4] Growth Score - The Growth Style Score emphasizes a company's financial health and future outlook, analyzing projected and historical earnings, sales, and cash flow [5] Momentum Score - The Momentum Style Score assesses stocks based on price trends and earnings outlook changes, helping investors capitalize on upward or downward price movements [6] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors who utilize multiple investing strategies [7] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +23.81% since 1988, significantly outperforming the S&P 500 [8][9] - There are over 800 top-rated stocks available, making it essential to use Style Scores to narrow down choices [9] Stock to Watch: Theravance Biopharma (TBPH) - Theravance Biopharma is a biopharmaceutical company focused on respiratory medicines, rated 2 (Buy) on the Zacks Rank with a VGM Score of A [12] - The company is particularly appealing to growth investors, with a Growth Style Score of A and a forecasted year-over-year earnings growth of 175% for the current fiscal year [13] - Recent upward revisions in earnings estimates and a strong average earnings surprise of +55.4% further enhance TBPH's investment appeal [13]

Shares of Theravance Biopharma (TBPH) have gained 1.7% over the past four weeks to close the last trading session at $18.79, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $26.71 indicates a potential upside of 42.2%.The average comprises seven short-term price targets ranging from a low of $13.00 to a high of $42.00, with a standard deviation of $11.1. While the lowest estimat ...

Group 1 - The article discusses the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1]

Core Viewpoint - Theravance Biopharma is focusing on ampreloxetine, an orphan drug aimed at treating neurogenic orthostatic hypotension in patients with multiple system atrophy, with pivotal Phase III study data expected in Q1 2026 [2][3]. Group 1: Product Overview - Ampreloxetine is designed to address a significant unmet need in symptomatic neurogenic orthostatic hypotension (nOH) [3]. - The drug is positioned as a once-daily oral medication that offers a durable treatment effect, potentially transforming the treatment landscape for affected patients [3]. Group 2: Clinical Development - The pivotal Phase III study, named CYPRESS, is nearing completion, with results anticipated in the first quarter of 2026 [2].

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Whil ...